Simone Steinbild

1.1k total citations
19 papers, 863 citations indexed

About

Simone Steinbild is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Simone Steinbild has authored 19 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Cancer Research and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Simone Steinbild's work include Cancer Treatment and Pharmacology (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Simone Steinbild is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Cancer, Lipids, and Metabolism (3 papers). Simone Steinbild collaborates with scholars based in Germany, United States and Austria. Simone Steinbild's co-authors include K. Mross, Annette Frost, Clemens Unger, Susanne Hedbom, Martin Büchert, Roland Heinig, Jörn Krätzschmar, Olaf Christensen, Ulrike Fasol and Oliver Boix and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Simone Steinbild

19 papers receiving 850 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simone Steinbild Germany 12 488 353 263 147 141 19 863
Mónica Musteanu Spain 14 552 1.1× 415 1.2× 149 0.6× 181 1.2× 73 0.5× 32 972
Annette Frost Germany 14 747 1.5× 462 1.3× 493 1.9× 184 1.3× 176 1.2× 29 1.4k
A. Craig Lockhart United States 17 477 1.0× 522 1.5× 261 1.0× 234 1.6× 82 0.6× 49 1.0k
Henry Xiong United States 11 769 1.6× 342 1.0× 303 1.2× 221 1.5× 43 0.3× 20 1.1k
Jean Mendiboure France 12 945 1.9× 410 1.2× 412 1.6× 197 1.3× 67 0.5× 17 1.6k
Gregory Friberg United States 18 722 1.5× 504 1.4× 318 1.2× 269 1.8× 91 0.6× 35 1.2k
Dominique de Valeriola Belgium 13 521 1.1× 305 0.9× 228 0.9× 192 1.3× 32 0.2× 47 887
Lisa Malburg United States 9 405 0.8× 493 1.4× 181 0.7× 99 0.7× 48 0.3× 14 780
Michael E. Menefee United States 15 610 1.3× 484 1.4× 209 0.8× 181 1.2× 123 0.9× 45 1.3k
Ulrike Tontsch-Grunt Austria 9 413 0.8× 656 1.9× 627 2.4× 129 0.9× 88 0.6× 20 1.4k

Countries citing papers authored by Simone Steinbild

Since Specialization
Citations

This map shows the geographic impact of Simone Steinbild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simone Steinbild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simone Steinbild more than expected).

Fields of papers citing papers by Simone Steinbild

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simone Steinbild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simone Steinbild. The network helps show where Simone Steinbild may publish in the future.

Co-authorship network of co-authors of Simone Steinbild

This figure shows the co-authorship network connecting the top 25 collaborators of Simone Steinbild. A scholar is included among the top collaborators of Simone Steinbild based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simone Steinbild. Simone Steinbild is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Mross, K., Annette Frost, Simone Steinbild, et al.. (2012). A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 18(9). 2658–2667. 262 indexed citations
3.
Frost, Annette, K. Mross, Simone Steinbild, et al.. (2012). Phase I Study of the Plk1 Inhibitor BI 2536 Administered Intravenously on Three Consecutive Days in Advanced Solid Tumours. Current Oncology. 19(1). 28–35. 62 indexed citations
4.
Mross, K. & Simone Steinbild. (2012). Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients. 1(1). 32–32. 25 indexed citations
5.
Steinbild, Simone, Annette Frost, Brian Z. Ring, Clemens Unger, & K. Mross. (2009). Phase II Study with 3rd- or 4th-Line Bendamustine (Flat Dose) Therapy in Patients with Metastatic Breast Cancer. Onkologie. 32(8-9). 488–492. 1 indexed citations
6.
Strumberg, Dirk, Beate Schultheis, Irenä us A. Adamietz, et al.. (2008). Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. British Journal of Cancer. 99(10). 1579–1585. 16 indexed citations
7.
Mross, K., Annette Frost, Simone Steinbild, et al.. (2008). Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 26(34). 5511–5517. 129 indexed citations
8.
Steinbild, Simone, J. Arends, Michael Medinger, et al.. (2007). Metronomic Antiangiogenic Therapy with Capecitabine and Celecoxib in Advanced Tumor Patients – Results of a Phase II Study. Oncology Research and Treatment. 30(12). 629–635. 34 indexed citations
9.
Steinbild, Simone, Annette Frost, R. Morant, et al.. (2007). A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. British Journal of Cancer. 97(11). 1480–1485. 80 indexed citations
10.
Hedbom, Susanne, Simone Steinbild, Annette Frost, et al.. (2007). Phase I study of BAY 73–4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors. Journal of Clinical Oncology. 25(18_suppl). 3593–3593. 7 indexed citations
11.
Unger, Clemens, Michael Medinger, Joachim Drevs, et al.. (2007). Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin. Clinical Cancer Research. 13(16). 4858–4866. 88 indexed citations
12.
Mross, K., Simone Steinbild, Martin Radtke, et al.. (2006). Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. European Journal of Cancer. 43(1). 55–63. 87 indexed citations
13.
Munzert, Gerd, Simone Steinbild, Annette Frost, et al.. (2006). A phase I study of two administration schedules of the Polo-like kinase 1 inhibitor BI 2536 in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3069–3069. 13 indexed citations
14.
Trommeshauser, Dirk, K. Mross, Simone Steinbild, et al.. (2006). 401 POSTER Pharmacokinetic characterization of BI 2536 - a novel Plk1 inhibitor - in advanced cancer patients. European Journal of Cancer Supplements. 4(12). 123–123. 2 indexed citations
15.
Steinbild, Simone, K. Mross, Dieter Köberle, et al.. (2006). Phase II study of Sorafenib (BAY 43–9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research—EWIV (CESAR). Journal of Clinical Oncology. 24(18_suppl). 3094–3094. 10 indexed citations
16.
Steinbild, Simone, et al.. (2005). Phase I study of BAY 43–9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3115–3115. 12 indexed citations
17.
Medinger, Michael, et al.. (2004). Die systemische Therapie des Kolonkarzinoms 2004. Praxis. 93(40). 1633–1644. 2 indexed citations
18.
Unger, Christian, Simone Steinbild, Michael Medinger, et al.. (2004). Phase I dose escalating study of PEG-PGA and DON (GlutaDON): A new amino acid depleting anti cancer drug approach. Journal of Clinical Oncology. 22(14_suppl). 3175–3175. 6 indexed citations
19.
Steinbild, Simone, Frank Baas, Peter Buss, et al.. (2003). Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 41(12). 618–619. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mónica Musteanu Breakdown of academic impact, for papers by Annette Frost Breakdown of academic impact, for papers by A. Craig Lockhart Breakdown of academic impact, for papers by Henry Xiong Breakdown of academic impact, for papers by Jean Mendiboure Breakdown of academic impact, for papers by Gregory Friberg Breakdown of academic impact, for papers by Dominique de Valeriola Breakdown of academic impact, for papers by Lisa Malburg Breakdown of academic impact, for papers by Michael E. Menefee Breakdown of academic impact, for papers by Ulrike Tontsch-Grunt
Rankless by CCL
2026